So you want straighter teeth, but think braces will hurt your chances for promotion to department head? No problem. There's an outfit in Santa Clara, California that has the answer.

Align Technology (NASDAQ: ALGN) makes the Invisalign system, a proprietary method for treating crooked teeth. Invisalign corrects the condition using a series of clear, nearly invisible, removable Aligners that gently move teeth to a desired final position. Because it does not use brackets and wires, Invisalign significantly reduces the aesthetic limitations of braces and is appropriate for treating adults and older teens. The firm also provides an Internet-based application that enables orthodontists to choose the correct Aligners by simulating sequential stages of tooth movement. 3M Company (NYSE: MMM) is a competitor.

The company pleased investors last week, when it reported Q1 EPS of ten cents and revenues of $63.8 million. Analysts had been looking for a loss of a penny and $58.5 million. Management also guided Q2 EPS to 10-12 cents (1 cent consensus), Q2 revenues to $72-74 million ($62.21M consensus), FY07 EPS to 30-38 cents (6 cent consensus) and FY07 revenues to $268.4-278.0M ($250.72M consensus). Deutsche Securities, Roth Capital and JMP Securities subsequently reiterated "buy" recommendations.

So you think straighter teeth will make all the difference, but can't see yourself wearing braces in the boardroom? No problem. There's an outfit in Santa Clara, California that has the answer.

Align Technology Inc. (NASDAQ:ALGN) makes the Invisalign system, a proprietary method for treating crooked teeth. Invisalign corrects the condition using a series of clear, nearly invisible, removable Aligners that gently move teeth to a desired final position. Because it does not use brackets and wires, Invisalign significantly reduces the aesthetic limitations of braces and is appropriate for treating adults and older teens.

The company pleased investors last week when it reported a Q4 loss of a penny per share and revenues of $55.2 million. Analysts had been looking for a fifteen cent loss and sales of $54 million. Management also guided Q1 EPS to 2-4 cents (beating the 5 cent loss consensus), Q1 revenues to $56.8-$59.8 million (compared to the $54.75M consensus), FY07 EPS to 15-27 cents (penny loss consensus) and FY07 revenues to $240-$255 million ($238.37M consensus).